[ET Net News Agency, 13 December 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said the company has received the Acceptance Notice issued by the National Medical
Products Administration (the NMPA). The supplemental new drug application (the sNDA) for
toripalimab (trade name: TUOYI, product code: JS001) in combination with standard
chemotherapy as the first-line treatment of patients with treatment-naive advanced
non-small cell lung cancer (NSCLC) with no EGFR or ALK tumour aberrations has been
accepted. (RC)